H.C. Wainwright adjusted the firm’s price target on Atossa Therapeutics (ATOS) to $25 from $7 and keeps a Buy rating on the shares. The firm cites the company’s 1-for-15 reverse stock split for the change.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
- Atossa Therapeutics announces addition of two biopharma executives to team
- VTI ETF Inflows Hold Steady Despite AI Sell-Off – 2/24/26
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26
- Atossa Therapeutics Launches New $50 Million ATM Program